Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (−) and ER (+) Breast Cancer

Bcl-2 is overexpressed in about a half of human cancers and 50–70% of breast cancer patients, thereby conferring resistance to conventional therapies and making it an excellent therapeutic target. Small interfering RNA (siRNA) offers novel and powerful tools for specific gene silencing and molecular...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ibrahim Tekedereli, S Neslihan Alpay, Ugur Akar, Erkan Yuca, Cristian Ayugo-Rodriguez, He-Dong Han, Anil K Sood, Gabriel Lopez-Berestein, Bulent Ozpolat
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier 2013-01-01
Colección:Molecular Therapy: Nucleic Acids
Materias:
apoptosis
autophagy
Bcl-2
breast cancer
chemotherapy
estrogen receptor
gene silencing
liposome
nanoparticles
nanotherapeutics
programmed cell deathsiRNA
Acceso en línea:http://www.sciencedirect.com/science/article/pii/S2162253116301780
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares